These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1390 related articles for article (PubMed ID: 27639764)

  • 1. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
    Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
    BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.
    Buss SJ; Emami M; Mereles D; Korosoglou G; Kristen AV; Voss A; Schellberg D; Zugck C; Galuschky C; Giannitsis E; Hegenbart U; Ho AD; Katus HA; Schonland SO; Hardt SE
    J Am Coll Cardiol; 2012 Sep; 60(12):1067-76. PubMed ID: 22883634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
    Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
    J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
    Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
    Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of patients with triphasic mitral flow with a mid-diastolic L wave: prognostic role of left atrial volume and N-terminal pro-brain natriuretic peptide.
    Kim SA; Son J; Shim CY; Choi EY; Ha JW
    Int J Cardiovasc Imaging; 2017 Sep; 33(9):1377-1384. PubMed ID: 28349264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of strain Doppler imaging in light-chain amyloidosis.
    Koyama J; Falk RH
    JACC Cardiovasc Imaging; 2010 Apr; 3(4):333-42. PubMed ID: 20394893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of tissue Doppler-derived Tei index and two-dimensional speckle tracking imaging derived longitudinal strain on predicting outcome of patients with light-chain cardiac amyloidosis.
    Liu D; Hu K; Herrmann S; Cikes M; Ertl G; Weidemann F; Störk S; Nordbeck P
    Int J Cardiovasc Imaging; 2017 Jun; 33(6):837-845. PubMed ID: 28265790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography.
    Zhang L; Zhou X; Wang J; Mu Y; Liu B; Lv W; Wang Y; Liu H; Liu H; Zhi G
    Int J Cardiovasc Imaging; 2017 Apr; 33(4):499-507. PubMed ID: 27878699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Utility of Brain Natriuretic Peptide and Left Ventricular Global Longitudinal Strain in Asymptomatic Patients With Significant Primary Mitral Regurgitation and Preserved Systolic Function Undergoing Mitral Valve Surgery.
    Alashi A; Mentias A; Patel K; Gillinov AM; Sabik JF; Popović ZB; Mihaljevic T; Suri RM; Rodriguez LL; Svensson LG; Griffin BP; Desai MY
    Circ Cardiovasc Imaging; 2016 Jul; 9(7):. PubMed ID: 27342145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-dimensional strain for the assessment of left ventricular function in low flow-low gradient aortic stenosis, relationship to hemodynamics, and outcome: a substudy of the multicenter TOPAS study.
    Bartko PE; Heinze G; Graf S; Clavel MA; Khorsand A; Bergler-Klein J; Burwash IG; Dumesnil JG; Sénéchal M; Baumgartner H; Rosenhek R; Pibarot P; Mundigler G
    Circ Cardiovasc Imaging; 2013 Mar; 6(2):268-76. PubMed ID: 23275349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Diastolic Strain Rate in Relation to Systolic and Diastolic Function and Prognosis in Aortic Stenosis.
    Dahl JS; Barros-Gomes S; Videbæk L; Poulsen MK; Issa IF; Carter-Storch R; Christensen NL; Kumme A; Pellikka PA; Møller JE
    JACC Cardiovasc Imaging; 2016 May; 9(5):519-28. PubMed ID: 27085434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis.
    Boynton SJ; Geske JB; Dispenzieri A; Syed IS; Hanson TJ; Grogan M; Araoz PA
    JACC Cardiovasc Imaging; 2016 Jun; 9(6):680-6. PubMed ID: 27209101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
    Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
    Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitive cardiac troponins and N-terminal pro-B-type natriuretic peptide in stable coronary artery disease: correlation with left ventricular function as assessed by myocardial strain.
    Smedsrud MK; Gravning J; Omland T; Eek C; Mørkrid L; Skulstad H; Aaberge L; Bendz B; Kjekshus J; Edvardsen T
    Int J Cardiovasc Imaging; 2015 Jun; 31(5):967-73. PubMed ID: 25788439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
    Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
    Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.